Neurology

The Pharmacy Times® Neurology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?

Multiple Sclerosis Drug Costs Nearly Tripled Over 7 Years

The release of generic versions of brand name drugs for patients with multiple sclerosis had little overall effect on the price increase.

FDA Approves Diazepam Nasal Spray for Intermittent, Stereotypic Seizure Activity

The diazepam nasal spray was granted 7 years of Orphan Drug Exclusivity by the FDA Office of Orphan Products Development.

Favorable Retention Rates with Perampanel in Patients with Epilepsy

Patients with epilepsy treated with perampanel during routine clinical care had favorable retention rates and sustained efficacy.

Perampanel Found to be Effective in Seizure Control in Patients with Partial-Onset Seizures

An analysis of efficacy and safety outcomes in patients receiving perampanel as first adjunctive antiepileptic drug found that almost half of the patients were seizure-free.

Immunoglobulin Levels are Reduced in Patients with Multiple Sclerosis, Study Finds

In this study, researchers wanted to evaluate the frequency of reduced immunoglobulin concentrations and its association with immunotherapy and disease course in 2 independent cohorts with multiple sclerosis.

FDA Approves First Generics for Common Multiple Sclerosis Drug

Fingolimod treats relapsing forms of multiple sclerosis in adult patients.

FDA Approves Riluzole Oral Film for Treatment of Amyotrophic Lateral Sclerosis

Riluzole oral film (Exservan, Aquestive Therapeutics) has received early-action approval from the FDA for the treatment of amyotrophic lateral sclerosis.

Midazolam Nasal Spray Treatment for Seizure Clusters to be Available in December

Approved by the FDA in May 2019, midazolam nasal spray CIV (Nayzilam, UCB) is the first nasal rescue treatment for seizure clusters in the United States.

Risdiplam Granted Priority Review for Spinal Muscular Atrophy

If approved, risdiplam (Genentech) would be the first at-home administered medicine for patients living with spinal muscular atrophy.

Top news of the day from across the health care landscape.

FDA Approves Biosimilar for Multiple Inflammatory Conditions

Officials with the FDA have approved adalimumab-afzb (Abrilada, Pfizer), a biosimilar to Humira, for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.

Cenobamate Leads to Significant Reductions in Adult Patients with Partial-Onset Seizures

Cenobamate is an investigational antiepileptic drug that has shown broad spectrum anticonvulsant activity in preclinical studies and seizure models.

The Pharmacy Times® Neurology resource center provides a home for all of the latest clinical information that both neurologists and pharmacists that work within the field could find valuable. With articles covering updates from the robust pipeline of novel neurological therapies, and the newest data from all phases of clinical trials and studies in the space, it also serves as a hub of coverage from ongoing conferences and annual meetings of neurological associations.